Apnimed, Inc. (APMD) IPO

Executive Summary

Apnimed, Inc. (APMD) priced its upsized initial public offering of 12,000,000 shares of common stock at $16.00 per share, the top of the marketed $14.00 to $16.00 range, and began trading on the Nasdaq Global Select Market on July 31, 2026. All shares are primary. The company is a late stage clinical pharmaceutical company with one clinical candidate, Oxnimbi, and no commercial revenue.

1. Gross proceeds are $192.0 million before underwriting discounts and expenses, rising to $220.8 million if the 1,800,000-share underwriters' option is exercised in full. The deal was upsized from the 10,000,000 shares marketed in the S-1/A and priced at the top of the range.
2. The offering was marketed at $14.00 to $16.00 on 10,000,000 shares with a 1,500,000-share option. Final terms are 12,000,000 shares at $16.00 with an 1,800,000-share option — more shares, higher price, larger greenshoe.
3. On approximately 40.0 million shares outstanding after the offering — the filing's ~38.0 million post-offering count plus the 2,000,000-share upsize — $16.00 implies roughly $640 million of market value at pricing; the count rises to approximately 41.8 million if the option is exercised in full.
4. The value driver is a date, not a number: the FDA accepted the Oxnimbi NDA in July 2026 and set a PDUFA goal action date of February 28, 2027.
5. The filing discloses that at the pre-NDA meeting the FDA raised the clinical meaningfulness of certain endpoint results, including the primary endpoint, and the limitations of the patient-reported outcomes, and indicated additional analyses and justification may be needed.
6. Two Phase 3 trials, LunAIRo and SynAIRgy, enrolled approximately 1,300 patients and both met the primary endpoint. Week-26 AHI reductions under the treatment policy estimand were 44.1% (SynAIRgy) and 33.7% (LunAIRo) versus 17.6% and 7.3% on placebo.
7. Cash was $46.9 million at March 31, 2026 and preliminarily approximately $172.8 million at June 30, 2026 after a $100.0 million SASS closing payment from Shionogi and $46.1 million net from the Tranche A term loan. Net losses were $128.2 million in 2025 and $111.3 million in 2024.
8. The remaining $100.0 million of the credit facility is locked behind FDA approval (Tranche B) and a $175.0 million net-sales test (Tranche C). The debt is secured by a lien on substantially all assets including intellectual property.
9. Syndicate of four: BofA Securities, Evercore ISI, Cantor, LifeSci Capital. Auditor: Deloitte & Touche LLP. 180-day lockup.
10. Final price and share count are from the company's pricing release dated July 30, 2026. Narrative terms are read from Form S-1/A, accession 0001193125-26-316811 (filed 2026-07-27); the 424B4 will restate the per-share dilution and ownership tables.
11. Day one: the first print crossed at $22.00 at 11:45:29 a.m. ET, 37.5% above the $16.00 offer, and the exchange open-close record carries the same $22.00 open. The session low was $16.12, twelve cents above the offer; the high was $29.15; the close was $25.00 — 56.25% above the offer and 13.64% above the open. The close is a two-of-three vendor consensus (Polygon and Finnhub at $25.00; FMP $24.69 dropped as the outlier).
12. Final price and share count are confirmed by the Form 424B4 filed July 31, 2026, accession 0001193125-26-328422: 12,000,000 shares at $16.00 for $192,000,000 gross, with an 1,800,000-share underwriters' option. These match the terms written from the July 30 pricing release exactly.

How this Dossier is built

A Bellipo Dossier is built from the filing itself. We aggregate the company's S-1 and its amendments, extract the disclosures that move a deal, and compile them into a single structured brief — the financial statements normalized into comparable lines, the use-of-proceeds split between primary and secondary, the capitalization and ownership table, the underwriting syndicate, insider selling, the auditor and its prior engagements, and the ranked risk factors. Every figure is traced to the source filing rather than the press release. The result is a desk-grade read of what the company disclosed, not what it announced — in plain English, in about five minutes.

Company Information

Apnimed is a late stage clinical pharmaceutical company with one clinical product candidate: AD109, proposed brand name Oxnimbi, a once-daily oral fixed-dose combination of a novel anti-muscarinic (aroxybutynin) and a selective norepinephrine reuptake inhibitor (atomoxetine) for obstructive sleep apnea. There is no approved product and no commercial revenue. Everything in this dossier is read from the filing.

Lead program as filed

The arc

1. The FDA, at the pre-NDA meeting, provided feedback about the clinical meaningfulness of certain endpoint results, including the primary endpoint, and the limitations of the patient-reported outcomes. The FDA indicated additional analyses and justification may be needed. The company states it submitted information in response in its NDA submission and plans to continue to address it and related requests as part of the FDA review process.
2. The 80 million U.S. OSA prevalence figure is from a study the company commissioned from Clarivate. It is a company-commissioned estimate, not an independent one.

Form S-1/A, accession 0001193125-26-316811 (filed 2026-07-27).

The Bellipo Take

A clinical-stage company with one candidate, no approved product and no commercial revenue, priced 12,000,000 primary shares at $16.00 — the top of its $14.00 to $16.00 range and upsized from 10,000,000 shares — for $192.0 million gross, ahead of an FDA decision date of February 28, 2027.

1. Both Phase 3 trials met their primary endpoint.LunAIRo (United States) and SynAIRgy (United States and Canada) together enrolled approximately 1,300 adults with mild to severe obstructive sleep apnea. Under the treatment policy estimand, mean apnea hypopnea index reductions at week 26 were 44.1% in SynAIRgy and 33.7% in LunAIRo, against 17.6% and 7.3% on placebo (p<=0.0001).
2. The review is already docketed.The NDA for Oxnimbi has been accepted with a PDUFA date of February 28, 2027. The filing puts a date on the single event this deal turns on rather than leaving it open-ended.
3. Cash was rebuilt before the raise.A $100.0 million closing payment from the disposition of the 50% SASS joint venture interest to Shionogi and $46.1 million of net Tranche A term loan proceeds lift preliminary unaudited cash to approximately $172.8 million at June 30, 2026, before offering proceeds.

1. The filing states substantial doubt about going concern.This is the company's own disclosure, carried in the summary risk factors: there is substantial doubt about its ability to continue as a going concern, and it says it must raise additional capital as and when needed.
2. The FDA has already questioned the endpoints.The filing discloses that the FDA has flagged the clinical meaningfulness of certain endpoint results and the limitations of the patient-reported outcomes. The gap between the treatment policy and on-treatment estimands is large in both trials, and that question sits inside the review, not outside it.
3. One candidate, one indication, no revenue.Oxnimbi is the sole clinical product candidate and there is no commercial revenue. Accumulated deficit was $329.6 million at March 31, 2026. The Tranche B and Tranche C term loans, $50.0 million each, unlock only on FDA regulatory authorization and on trailing-twelve-month net sales of $175.0 million respectively — neither is available today.

Bottom line

The book answered before the regulator did: upsized to 12,000,000 shares and priced at the top of the range for $192.0 million gross. The first session tested that answer and did not undo it — the stock opened at $22.00, traded down to $16.12, twelve cents above the offer, and closed at $25.00, 56.25% above where the deal priced. Everything here is still downstream of one date. The trials read out positive and the review has a deadline, but the company funds itself to that deadline with a balance sheet it repaired weeks before filing, and the regulator has already put its question on the record.

Form S-1/A, accession 0001193125-26-316811 (filed 2026-07-27).

S-1 Deep Dive

Key terms

Related IPO dossiers